Trial reportAddiction (Abingdon, England)2012
Double-blind placebo-controlled evaluation of the PROMETA™ protocol for methamphetamine dependence.
Trial report in Addiction (Abingdon, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 4 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Evidence-based consensus guidelines for the pharmacological management of substance dependence: Recommendations from the British Association for Psychopharmacology.Journal of psychopharmacology (Oxford, England) · 2026Guideline
- Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review.CNS drugs · 2020Pooled it
- Use of Gabapentin in the Treatment of Substance Use and Psychiatric Disorders: A Systematic Review.Frontiers in psychiatry · 2019Pooled it
- Methamphetamine-Related Disorders.Deutsches Arzteblatt international · 2017Guideline
- Sustained-release methylphenidate in methamphetamine dependence treatment: a double-blind and placebo-controlled trial.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2015Trial
- Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder.Addiction (Abingdon, England) · 2014Trial
- Artificial intelligence-based drug repurposing with electronic health record clinical corroboration: A case for ketamine as a potential treatment for amphetamine-type stimulant use disorder.Addiction (Abingdon, England) · 2025Article
- Therapeutic targeting of neuroinflammation in methamphetamine use disorder.Future medicinal chemistry · 2025Review
- Pharmacological Treatments for Methamphetamine Use Disorder: Current Status and Future Targets.Substance abuse and rehabilitation · 2024Review
- Psychosocial and pharmacologic interventions for problematic methamphetamine use: Findings from a scoping review of the literature.PloS one · 2023Article
- Gabapentin for the treatment of alcohol use disorder.Expert opinion on investigational drugs · 2018Review
- Tamoxifen and amphetamine abuse: Are there therapeutic possibilities?Journal of chemical neuroanatomy · 2017Review
- Adding Genetic Testing to Evidence-Based Guidelines to Determine the Safest and Most Effective Chronic Pain Treatment for Injured Workers.International journal of biomedical science : IJBS · 2015Article
- Gabapentin Therapy in Psychiatric Disorders: A Systematic Review.The primary care companion for CNS disorders · 2015Article
- Methamphetamine: an update on epidemiology, pharmacology, clinical phenomenology, and treatment literature.Drug and alcohol dependence · 2014Review
- Combination pharmacotherapies for stimulant use disorder: a review of clinical findings and recommendations for future research.Expert review of clinical pharmacology · 2014Review
- Pharmacotherapy of amphetamine-type stimulant dependence: an update.Drug and alcohol review · 2013Review
- Commentary on Ling et al. (2012): The PROMETA™ treatment does not reduce methamphetamine use.Addiction (Abingdon, England) · 2012Article
- Psychiatric Uses of Gabapentin.Innovations in clinical neuroscienceReview
Corrections and comments
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
aimsTo evaluate the efficacy and safety of the PROMETA™ Protocol for treating methamphetamine dependence.
designA double-blind, placebo-controlled 108-day study with random assignment to one of two study conditions: active medication with flumazenil (2 mg infusions on days 1, 2, 3, 22, 23), gabapentin (1200 mg to day 40) and hydroxazine (50 mg to day 10) versus placebo medication (with active hydroxazine only).
settingThree substance abuse treatment clinics: two in-patient, one out-patient.
participantsTreatment-seeking, methamphetamine-dependent adults (n = 120). MEASUREMENTS: Primary outcome was percentage of urine samples testing negative for methamphetamine during the trial.
findingsNo statistically significant between-group differences were detected in urine drug test results, craving, treatment retention or adverse events.
conclusionsThe PROMETA protocol, consisting of flumazenil, gabapentin and hydroxyzine, appears to be no more effective than placebo in reducing methamphetamine use, retaining patients in treatment or reducing methamphetamine craving.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.